Acquired haemophilia A (AHA) is a rare bleeding disorder caused by inhibitory
autoantibodies against coagulation factor VIII (FVIII). AHA is a disease that most commonly …

Emicizumab, a monoclonal bispecific antibody that mimics the function of activated factor VIII
(FVIII), is currently licensed for prophylactic use in patients with congenital hemophilia A with …

Background Emicizumab is a bispecific antibody that mimics the cofactor function of
activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A …

Clot waveform analysis (CWA) is a recently developed global coagulation assessment,
based on the continuous observation of changes in light transmittance, absorbance, or light …

Acquired hemophilia A (AHA), a rare but life-threatening disorder, most commonly occurs in
older people and during pregnancy. During the coronavirus disease 2019 (COVID-19) …

Abstract Introduction Acquired haemophilia A (AHA) is a rare disease. The risk factors have
yet to be studied. Aim We aimed to identify risk factors for late‐onset AHA in Japan. Methods …

Abstract Introduction Acquired hemophilia A (AHA) is a rare autoimmune hemorrhagic
disease occurring in several underlying conditions. Drug‐associated AHA (D‐AHA) is poorly …

Acquired haemophilia A (AHA) is an autoimmune bleeding disorder caused by
autoantibodies blocking coagulation factor VIII (FVIII). Haemostatic management of AHA and …

Purpose Several case reports of acquired hemophilia A (AHA) following COVID‐19 vaccines
were recently published. A possible increased incidence of AHA during the COVID‐19 …

Abstract Introduction Acquired haemophilia A (AHA) is a rare and potentially life‐threatening
bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII) …